Ongoing clinical trials investigate novel immunotherapy combinations and strategies (e.g., T-VEC, BEMPEG, incorporation or sequencing of targeted therapy, and incorporation or sequencing of radiotherapy), and focus on poor prognosis groups (e.g., high tumor burden/LDH levels, anti-PD-1 refractory melanoma, and brain metastases). Here, PDCD1 is linked to neoplasm.